The objective of the study was to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.
Psoriasis was a chronic disease that was affecting skin, the scalp and joints. Scalp psoriasis was very common and was having an important impact on people's life. Primary objective of scalp psoriasis treatments was to gain initial and rapid control of the disease process with a minimum of side-effects and improve patient quality of life. Still, one of the unmet needs of scalp psoriasis therapies was the maintenance of a long-term remission. For corticosteroids in particular, one of the drawbacks was the disease recurrences after cessation of the treatment. Therefore, the establishment of a modified corticosteroid dosing regimen that would allow remission with minimal side-effects was suitable. The purpose of this study was to assess how long a patient successfully maintained in a good condition after use of Clobex® shampoo only twice a week.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
288
Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
centre de Recherche Dermatologique du Québec
Québec, Canada
Maintenance Phase: Time to First Relapse
Time to first relapse was defined as the duration between baseline of maintenance phase and the visit where the relapse occurred. The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS \>2.
Time frame: Baseline up to 24 Weeks
Initial Phase: Percentage of Participants With Global Severity Scores
Global severity score was evaluated on a scale of 0-4 and it was categorized as; Clear (score 0); no clinical signs or symptoms detected (hyperpigmentation or residual red coloration might be present), very mild (score 1); only very slight signs or symptoms detected (e.g., very fine scaling or slight erythema), mild (score 2); slight signs or symptoms detected (e.g., mild erythema and scaling, eventually associated to some barely detectable plaque elevation), moderate (score 3); moderate or clearly detectable signs or symptoms (e.g., definite redness with obvious scaling on a plaque that was elevated above skin level), severe (score 4); severe signs or symptoms detected (e.g., intense redness, profuse shedding, definite plaque thickness was most often present) where 0 indicates best and 4 indicates worst. Percentage of participants with GSS was reported. Missing Clobex® shampoo data were imputed using last observation carried forward (LOCF).
Time frame: Baseline, Weeks 2 and 4 LOCF
Initial Phase: Percentage of Participants With Pruritus Scores
Pruritus (itching sensation) score of were evaluated on a scale from 0 - 3 (0 = None \[no itching\], 1 = Mild \[slight itching\], not really bothersome), 2 = Moderate \[definite itching that is somewhat bothersome; without loss of sleep\], and 3 = severe \[intense itching that has caused pronounced discomfort; night rest interrupted and excoriations of the skin from scratching may be present\]) , where 0 indicates best and 3 indicates worst. Percentage of participants with pruritus score was reported. Missing Clobex® shampoo data were imputed using last observation carried forward (LOCF).
Time frame: Baseline, Weeks 2 and 4 LOCF
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Initial Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores
Individual sign scores of erythema (abnormal redness of skin), scaling (scales attached to the scalp), plaque thickening (a thickening or elevation of a circumscribed lesion or plaque) were evaluated on a scale of 0-4; 0= none , 1= mild , 2=moderate , 3= severe, 4= very severe, where 0 indicates best and 4 indicates worst. Percentage of participants with individual signs (erythema, scaling, and plaque thickening) scores were reported. Missing Clobex® shampoo data were imputed using last observation carried forward (LOCF).
Time frame: Baseline, Weeks 2 and 4 LOCF
Maintenance Phase: Percentage of Participants Who Had First Relapse
The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS \>2. Relapse was categorized into relapse or no relapse. Percentage of participants with relapse were reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Maintenance Phase: Percentage of Participants With Scalp Psoriasis Pruritus Score at First Time of Relapse
Pruritus (itching sensation) score of were evaluated on a scale from 0 - 3 (0 = None \[no itching\], 1 = Mild \[slight itching, not really bothersome\], 2 = Moderate \[definite itching that is somewhat bothersome; without loss of sleep\], and 3 = severe \[intense itching that has caused pronounced discomfort; night rest interrupted and excoriations of the skin from scratching may be present\]) , where 0 indicates best and 3 indicates worst. Percentage of participants with scalp psoriasis pruritus score at first relapse was reported.
Time frame: Baseline up to Week 24
Maintenance Phase: Percentage of Participants With Individual Category of Scalp Psoriasis Individual Signs (Erythema, Scaling and Plaque Thickening) Scores at First Time of Relapse
The first relapse was defined as the first time during the maintenance phase when participant presented with a GSS \>2. Individual sign scores of erythema were evaluated on a scale of 0-4 (0= none, 1= mild, 2=moderate, 3= severe, 4= very severe), where 0 indicates best and 4 indicates worst. Percentage of participants with individual signs (erythema, scaling and plaque thickening) scores were reported. There were no participants in scaling category with 0 score.
Time frame: Baseline up to Week 24
Maintenance Phase: Percentage of Participants With Number of Relapses Experienced
Number of relapses of participants were categorized as 0; zero relapse, 1; one relapse, 2; two relapse, 3; three relapse, 4; two consecutive relapses. Percentage of participants with total number of relapses experienced during maintenance period was reported.
Time frame: Baseline up to Week 28